Om

TenNor Therapeutics (Suzhou) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of differentiated therapies for diseases associated with bacterial infections and bacterial metabolism. Headquartered in Suzhou, China, and founded in 2013, the company concentrates on innovative anti-infective and microbiome-related drug candidates targeting unmet medical needs. Its pipeline includes Rifasutenizole (TNP-2198) for Helicobacter pylori infection and Rifaquizinone (TNP-2092) in various formulations for indications such as periprosthetic joint infection, acute bacterial skin and skin structure infections, left ventricular assist device infections, and gut microbiota–related conditions like hepatic encephalopathy and irritable bowel syndrome with diarrhea. Additional candidates include narrow and broad-spectrum small molecules targeting resistant bacterial strains, nontuberculous mycobacterial pulmonary disease, and metabolic disorders. TenNor Therapeutics (Suzhou) Limited operates primarily in the biotechnology and medical research sector, contributing to the anti-infective and microbiome therapeutics segments of the global healthcare market.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I TENNOR THERAPEUTICS SUZHOU MED ENDAVU: Køb TenNor Therapeutics Suzhou ($6872) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i TenNor Therapeutics Suzhou, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.